Attenuation of the toxicity of a pyrrolizidine alkaloid (monocrotaline) by metabolic inhibition.
D000818:Animals; D000963:Antimetabolites / Q000494:pharmacology*; D006332:Cardiomegaly / Q000139:chemically induced / Q000517:prevention & control; D006984:Hypertrophy; D008168:Lung / Q000187:drug effects / Q000473:pathology; D008297:Male; D008862:Microsomes, Liver / Q000201:enzymology; D006899:Mixed Function Oxygenases / Q000037:antagonists & inhibitors; D011763:Pyrrolizidine Alkaloids / Q000037:antagonists & inhibitors* / Q000633:toxicity; D051381:Rats; D013438:Sulfhydryl Compounds / Q000494:pharmacology
D000963:Antimetabolites; D011763:Pyrrolizidine Alkaloids; D013438:Sulfhydryl Compounds; D006899:Mixed Function Oxygenases